These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 26538316)

  • 1. Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease.
    Kalimutho M; Parsons K; Mittal D; López JA; Srihari S; Khanna KK
    Trends Pharmacol Sci; 2015 Dec; 36(12):822-846. PubMed ID: 26538316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the Molecular Subtypes of Triple Negative Breast Cancer: Understanding the Diversity to Progress the Field.
    Yam C; Mani SA; Moulder SL
    Oncologist; 2017 Sep; 22(9):1086-1093. PubMed ID: 28559413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Triple Negative Breast Cancer: A Tale of Two Decades.
    Ali AM; Ansari JAK; El-Aziz NMA; Abozeed WN; Warith AMA; Alsaleh K; Nabholtz JM
    Anticancer Agents Med Chem; 2017; 17(4):491-499. PubMed ID: 27456662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The evolving management of metastatic triple negative breast cancer.
    Malhotra MK; Emens LA
    Semin Oncol; 2020 Aug; 47(4):229-237. PubMed ID: 32563561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
    Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
    Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.
    Bianchini G; Balko JM; Mayer IA; Sanders ME; Gianni L
    Nat Rev Clin Oncol; 2016 Nov; 13(11):674-690. PubMed ID: 27184417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triple negative breast cancer: Emerging therapeutic modalities and novel combination therapies.
    Lee A; Djamgoz MBA
    Cancer Treat Rev; 2018 Jan; 62():110-122. PubMed ID: 29202431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The exploration of contrasting pathways in Triple Negative Breast Cancer (TNBC).
    Narrandes S; Huang S; Murphy L; Xu W
    BMC Cancer; 2018 Jan; 18(1):22. PubMed ID: 29301506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triple-negative breast cancer: molecular subtypes and targeted therapy.
    Hirshfield KM; Ganesan S
    Curr Opin Obstet Gynecol; 2014 Feb; 26(1):34-40. PubMed ID: 24346128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triple negative breast cancer chemosensitivity and chemoresistance: current advances in biomarkers indentification.
    Guestini F; McNamara KM; Ishida T; Sasano H
    Expert Opin Ther Targets; 2016 Jun; 20(6):705-20. PubMed ID: 26607563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent therapeutic trends and promising targets in triple negative breast cancer.
    Hwang SY; Park S; Kwon Y
    Pharmacol Ther; 2019 Jul; 199():30-57. PubMed ID: 30825473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triple-negative breast cancer: advancements in characterization and treatment approach.
    Hurvitz S; Mead M
    Curr Opin Obstet Gynecol; 2016 Feb; 28(1):59-69. PubMed ID: 26694831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of resistance of chemotherapy in early-stage triple negative breast cancer (TNBC).
    Wein L; Loi S
    Breast; 2017 Aug; 34 Suppl 1():S27-S30. PubMed ID: 28668293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting triple negative breast cancer with histone deacetylase inhibitors.
    Fedele P; Orlando L; Cinieri S
    Expert Opin Investig Drugs; 2017 Nov; 26(11):1199-1206. PubMed ID: 28952409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
    Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
    Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of the androgen receptor in triple-negative breast cancer.
    Rampurwala M; Wisinski KB; O'Regan R
    Clin Adv Hematol Oncol; 2016 Mar; 14(3):186-93. PubMed ID: 27058032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subtyping of triple-negative breast cancer: implications for therapy.
    Abramson VG; Lehmann BD; Ballinger TJ; Pietenpol JA
    Cancer; 2015 Jan; 121(1):8-16. PubMed ID: 25043972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triple-negative breast cancer and the potential for targeted therapy.
    Jhan JR; Andrechek ER
    Pharmacogenomics; 2017 Nov; 18(17):1595-1609. PubMed ID: 29095114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PIM1: a promising target in patients with triple-negative breast cancer.
    Zhao W; Qiu R; Li P; Yang J
    Med Oncol; 2017 Aug; 34(8):142. PubMed ID: 28721678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic Implications of the Molecular and Immune Landscape of Triple-Negative Breast Cancer.
    Gregório AC; Lacerda M; Figueiredo P; Simões S; Dias S; Moreira JN
    Pathol Oncol Res; 2018 Oct; 24(4):701-716. PubMed ID: 28913723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.